The FDA just approved Medtronic’s latest insulin pump, called the MiniMed Paradigm REAL-Time Revel System – this is Medtronic’s first new pump platform to be approved in...

A thorough review and “how-to” on the drug Symlin (Amylin’s pramlintide).

Kelly muses on the future of GLP-1 agonists and bariatric surgery.

Earlier this week, the FDA chose not to approve the weight-loss drug Qnexa. Qnexa is a combination of two currently approved drugs: phentermine, which is approved for...

Imagine dreaming about waking up alive inside a body bag. Vietnam veteran Urban Miyares did, but it wasn’t exactly a dream...

CVS recently announced the introduction of new monitoring services for people with diabetes offered through its MinuteClinic walk-in healthcare clinics. Dubbed...

A girl can dream, right? (...of cures and new insulins...)

Kelly here, the founder of diaTribe . Are you a woman interested in connecting with other women with diabetes and learning more about the unique challenges of diabetes?...

The American Diabetes Association is putting out an expanded third edition of their helpful book The Uncomplicated Guide to Diabetes Complications. In addition to advice...

Kerri Morrone Sparling gives her take on the pros and cons of CGM.

Novo Nordisk continues to make headway in the development of Degludec and DegludecPlus, the company’s two new “next-generation” insulins. The company recently announced...

(S)he said what?!?

Novo Nordisk’s “next-generation” basal insulin degludec. Novo Nordisk has released promising data from a 7,000-participant clinical trial for its next-generation basal...

Medtronic and Bayer have announced that they will partner over the next several years to develop “innovative next-generation diabetes management systems for patients...

We discuss the “motivated patient” and highlights from the American Association of Diabetes Educators’ annual meeting as well as big changes here at diaTribe …

New insulins on the horizon are designed to be taken three times a week. We’ve just heard that research at Novo Nordisk is moving quickly on two new insulins, one dubbed...

Metformin moonlights as a preventative cancer treatment.

Puzzled by the recent FDA decisions? Dr. Sanjay Kaul discusses the regulatory environment for diabetes and obesity medications.

Following on the heels of the decision for Bydureon, the FDA also decided last week not to approve Arena Pharmaceutical’s new weight loss drug Lorqess (lorcaserin). But...

In June, Insulet announced the acquisition of Neighborhood Diabetes, a medical equipment distributor that specializes in consumer sales of diabetes supplies. The company...